DETECTION AND PURIFICATION OF ANTIIDIOTYPIC ANTIBODY AGAINST ANTI-DNA IN INTRAVENOUS IMMUNE GLOBULIN

被引:29
作者
EVANS, MJ [1 ]
SUENAGA, R [1 ]
ABDOU, NI [1 ]
机构
[1] ST LUKES HOSP,EVANS IMMUNOL RES LAB,C-LEVEL,4400 WORNALL RD,KANSAS CITY,MO 64111
关键词
ANTIIDIOTYPES; INTRAVENOUS IMMUNE GLOBULIN (IVIG); LUPUS;
D O I
10.1007/BF00918187
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pooled normal human IgG for therapeutic use, following depletion of anti-DNA, anti-Fc, and anti-F(ab')2 of normal IgG, expressed antiidiotypic activity against anti-DNA derived from lupus sera. The antiidiotype enriched by elution from anti-DNA affinity columns bound directly to anti-DNA IgG and inhibited the binding of lupus sera to DNA but did not bind to normal IgG or inhibit the binding of anti-tetanus toxoid to tetanus toxoid. Antiidiotypes in pooled normal sera may have a role in the clinical improvement seen in patients with autoimmune diseases receiving intravenous immune globulin.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 24 条
[1]   THE IDIOTYPE ANTIIDIOTYPE NETWORK IN HUMAN AUTOIMMUNITY [J].
ABDOU, NI .
JOURNAL OF CLINICAL IMMUNOLOGY, 1985, 5 (06) :365-369
[2]   NETWORK THEORY IN AUTOIMMUNITY - INVITRO SUPPRESSION OF SERUM ANTI-DNA ANTIBODY-BINDING TO DNA BY ANTI-IDIOTYPIC ANTIBODY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ABDOU, NI ;
WALL, H ;
LINDSLEY, HB ;
HALSEY, JF ;
SUZUKI, T .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (05) :1297-1304
[3]  
ABDOU NI, 1986, IDIOTYPES, P95
[4]  
AKASHI K, 1990, J RHEUMATOL, V17, P375
[5]  
BERCHTOLD P, 1989, BLOOD, V74, P2414
[6]   NORMAL IMMUNOGLOBULIN-G (IGG) FOR THERAPEUTIC USE (INTRAVENOUS IG) CONTAIN ANTIIDIOTYPIC SPECIFICITIES AGAINST AN IMMUNODOMINANT, DISEASE-ASSOCIATED, CROSS-REACTIVE IDIOTYPE OF HUMAN ANTI THYROGLOBULIN AUTOANTIBODIES [J].
DIETRICH, G ;
KAZATCHKINE, MD .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (03) :620-625
[7]   IGG THERAPY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - 2 CASE-REPORTS [J].
GAEDICKE, G ;
TELLER, WM ;
KOHNE, E ;
DOPFER, R ;
NIETHAMMER, D .
BLUT, 1984, 48 (06) :387-390
[8]  
GAJDOS P, 1984, LANCET, V1, P406
[9]  
HATFIELD M, 1987, CLIN EXP IMMUNOL, V70, P26
[10]  
IMBACH P, 1981, LANCET, V1, P1228